Argen X Stock Quote ARGX - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

644.00

Bid

641.00

Ask

646.00

Volume

86,834

641.60 Day's Range 650.40

322.50 52 Week Range 650.40

Market Cap

38.121B

Previous Close

642.40

Open

644.00

Last Trade

644

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

60,213

Shares Outstanding

59,194,000

Dividend Yield

PE Ratio

-129.20

Earnings Per Share (EPS)

-4.98

Revenue

1.27B

Net Profit

-295.05M

Sector

Coml Physical, Biologcl Resh

Industry

Coml Physical, Biologcl Resh

Website

www.argenx.com

Headquarters

Amsterdam, North Holland, Nld

Founded

Argen X SE is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker ARGX. The last closing price for Argen X was 642.40 €. Over the last year, Argen X shares have traded in a share price range of 322.50 € to 650.40 €.

Argen X currently has 59,194,000 shares outstanding. The market capitalization of Argen X is 38.03 € billion. Argen X has a price to earnings ratio (PE ratio) of -129.20.

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio approved in Japan for three indications – first...

argenx to Present at Upcoming Investor Conferences

November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for...

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am ET Amsterdam, the Netherlands— argenx...

argenx to Participate at Upcoming Investor Conferences

November 5, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference...

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024

October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions

Long-term and real-world data of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability...

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	39	6.44628099174	605	650.4	598.8	63859	628.30984792	DE
4	63	10.843373494	581	650.4	577.4	59355	610.21172508	DE
12	140.2	27.8285033744	503.8	650.4	500	60213	573.61732661	DE
26	223.8	53.2603522132	420.2	650.4	417.3	59934	515.92497705	DE
52	280.7	77.2639691715	363.3	650.4	322.5	60329	437.76901953	DE
156	366	131.654676259	278	650.4	224.1	65008	381.27394554	DE
260	492.9	326.207809398	151.1	650.4	93.05	74523	302.53716619	DE

ARGX - Frequently Asked Questions (FAQ)

What is the current Argen X share price?

The current share price of Argen X is 644.00 €

How many Argen X shares are in issue?

Argen X has 59,194,000 shares in issue

What is the market cap of Argen X?

The market capitalisation of Argen X is EUR 38.03B

What is the 1 year trading range for Argen X share price?

Argen X has traded in the range of 322.50 € to 650.40 € during the past year

What is the PE ratio of Argen X?

The price to earnings ratio of Argen X is -129.2

What is the cash to sales ratio of Argen X?

The cash to sales ratio of Argen X is 30.05

What is the reporting currency for Argen X?

Argen X reports financial results in USD

What is the latest annual turnover for Argen X?

The latest annual turnover of Argen X is USD 1.27B

What is the latest annual profit for Argen X?

The latest annual profit of Argen X is USD -295.05M

What is the registered address of Argen X?

The registered address for Argen X is LAARDERHOOGTWEG 25, AMSTERDAM, NORTH HOLLAND, 1101 EB

What is the Argen X website address?

The website address for Argen X is www.argenx.com

Which industry sector does Argen X operate in?

Argen X operates in the COML PHYSICAL, BIOLOGCL RESH sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MLCOTCoretech 5	0.012 € (140.00%)	90.21k
ALCABCabasse SA	0.72 € (41.18%)	16.96k
ALAGOEPango SA	0.1828 € (21.87%)	9.37M
LEBLLcx Leblanc Chr	0.356 € (18.67%)	4
ALALOAcheterLouerFR	0.11 € (15.55%)	73.87k
BNBSTonner Drones	0.001 € (-50.00%)	23.99k
DBVDBV Technologies	0.875 € (-23.91%)	4.89M
MLCOUCourbet	1.75 € (-15.87%)	51
MLAZRThe Azur Selection SA	1.00 € (-15.25%)	130.18k
PROACProactis SA	0.0565 € (-13.74%)	560
ATOAtos SE	0.002 € (0.00%)	1.75B
BCPBanco Comercial Portugues SA	0.4802 € (0.04%)	53.25M
ALCYBCybergun	0.0001 € (0.00%)	20.24M
EDPEDP SA	2.974 € (-4.77%)	15.95M
ALVERVergnet	0.0018 € (0.00%)	15.63M